Microbiological Profile of Blood Stream Infections in Febrile Neutropenic Patients at a Tertiary Care Teaching Hospital in Rishikesh, UttarakhandSource(s) of Support None.
Context Febrile neutropenia is a serious complication of chemotherapy affecting patients with both hematological and solid malignancies, respectively. To the best of our knowledge, there is paucity of literature from Uttarakhand, India on microbiological profile of blood stream infections (BSIs) in febrile neutropenic patients.
Aims The study aims to generate preliminary data on microbiological profile and antibiotic resistance pattern of BSIs in febrile neutropenic patients.
Settings and Design The design involved cross-sectional study from January 1, 2019 to July 31, 2019.
Methods and Materials Data of nonrepetitive paired peripheral blood samples obtained from 306 consecutive febrile neutropenic cancer patients of all age groups and both sexes, for culture and sensitivity testing, were retrospectively analyzed. All blood samples were subjected to aerobic culture using BACT/ALERT three-dimensional microbial detection system. Growth obtained in culture was identified by conventional biochemical methods. Antibiotic susceptibility testing of bacterial isolates was performed using modified Kirby Bauer disk diffusion method.
Statistical Analysis Used Fisher’s exact test was used for the analysis.
Results Mean age ± SD of the study population was 32.39 ± 10.56 years with a male to female ratio of 1.55:1. 74.18% of the blood samples were received from patients suffering from hematological malignancies. Microbiologically confirmed BSIs were observed in 27.1% patients. Gram-negative bacilli were predominantly isolated in culture with Klebsiella spp. being the most common. Percentage resistance values of gram-negative bacilli to aminoglycosides, β-lactam/β-lactamase inhibitor combinations, fluoroquinolones, cephalosporins, carbapenems, chloramphenicol, ampicillin, co-trimoxazole, and doxycycline were 26.6 to 91.7%, 8.3 to 86.6%, 10 to 66.7%, 13.3 to 73.3%, 8.3 to 73.3%, 80 to 93.3%, 13.3 to 20%, 16.7 to 66.6%, and 13.3 to 16.7%, respectively.
Conclusion Implementation of antimicrobial stewardship program along with hospital infection control practices is needed for preventing BSIs due to MDR organisms.
02 September 2020 (online)
Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India
- 1 Freifeld AG, Bow EJ, Sepkowitz KA. et al. Infectious Diseases Society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2011; 52 (04) e56-e93
- 2 Klastersky J. Management of fever in neutropenic patients with different risks of complications. Clin Infect Dis 2004; 39 (Suppl. 01) S32-S37
- 3 Jacob LA, Lakshmaiah KC, Govindbabu K. et al. Clinical and microbiological profile of febrile neutropenia in solid tumors and hematological malignancies at a tertiary cancer care center in South India. Indian J Cancer 2014; 51 (04) 464-468
- 4 Liu CY, Lai YC, Huang LJ. et al. Impact of bloodstream infections on outcome and the influence of prophylactic oral antibiotic regimens in allogeneic hematopoietic SCT recipients. Bone Marrow Transplant 2011; 46 (09) 1231-1239
- 5 Penack O, Becker C, Buchheidt D. et al. Management of sepsis in neutropenic patients: 2014 updated guidelines from the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO). Ann Hematol 2014; 93 (07) 1083-1095
- 6 Jeddi R, Achour M, Amor RB. et al. Factors associated with severe sepsis: prospective study of 94 neutropenic febrile episodes. Hematology 2010; 15 (01) 28-32
- 7 Kang CI, Song JH, Chung DR. et al. Korean Network for Study of Infectious Diseases (KONSID). Risk factors and pathogenic significance of severe sepsis and septic shock in 2286 patients with gram-negative bacteremia. J Infect 2011; 62 (01) 26-33
- 8 Trecarichi EM, Tumbarello M. Antimicrobial-resistant gram-negative bacteria in febrile neutropenic patients with cancer: current epidemiology and clinical impact. Curr Opin Infect Dis 2014; 27 (02) 200-210
- 9 Paul M, Dickstein Y, Borok S, Vidal L, Leibovici L. Empirical antibiotics targeting Gram-positive bacteria for the treatment of febrile neutropenic patients with cancer. Cochrane Database Syst Rev 2014; 1 (01) CD003914
- 10 Amit S, Mishali H, Kotlovsky T, Schwaber MJ, Carmeli Y. Bloodstream infections among carriers of carbapenem-resistant Klebsiella pneumoniae: etiology, incidence and predictors. Clin Microbiol Infect 2015; 21 (01) 30-34
- 11 Ortega M, Marco F, Soriano A. et al. Analysis of 4758 Escherichia coli bacteraemia episodes: predictive factors for isolation of an antibiotic-resistant strain and their impact on the outcome. J Antimicrob Chemother 2009; 63 (03) 568-574
- 12 Viale P, Giannella M, Lewis R, Trecarichi EM, Petrosillo N, Tumbarello M. Predictors of mortality in multidrug-resistant Klebsiella pneumoniae bloodstream infections. Expert Rev Anti Infect Ther 2013; 11 (10) 1053-1063
- 13 Feld R. Bloodstream infections in cancer patients with febrile neutropenia. Int J Antimicrob Agents 2008; 32 (Suppl. 01) S30-S33
- 14 Perez F, Adachi J, Bonomo RA. Antibiotic-resistant gram-negative bacterial infections in patients with cancer. Clin Infect Dis 2014; 59 (Suppl. 05) S335-S339
- 15 Collee JG, Miles RS, Watt B. Tests for the identification of bacteria. In: Collee JG, Fraser AG, Marimon BP, Simmons A. eds. Mackie & Mc Cartney Practical Medical Microbiology. 14th ed. New Delhi: Elsevier; 2007. (reprint): 131-149
- 16 Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing. 29th Informational Supplement. CLSI Document M100. Wayne, PA: Clinical and Laboratory Standards Institute; 2019
- 17 European Committee on Antimicrobial Susceptibility Testing (EUCAST). Breakpoint tables for interpretation of MICs and zone diameters. Version 2019:9. Available at: http://www.eucast.org. Accessed December 30, 2019
- 18 Sickles EA, Greene WH, Wiernik PH. Clinical presentation of infection in granulocytopenic patients. Arch Intern Med 1975; 135 (05) 715-719
- 19 Safdar A, Armstrong D. Infections in patients with hematologic neoplasms and hematopoietic stem cell transplantation: neutropenia, humoral, and splenic defects. Clin Infect Dis 2011; 53 (08) 798-806
- 20 Babu KG, Lokanatha D, Lakshmaiah KC. et al. Bloodstream infections in febrile neutropenic patients at a tertiary cancer institute in South India: a timeline of clinical and microbial trends through the years. Indian J Med Paediatr Oncol 2016; 37 (03) 174-182
- 21 Parikh S, Goswami P, Anand A. et al. Clinical and microbiological profile of infections during induction phase of acute myeloid leukemia. Gulf J Oncolog 2018; 1 (27) 18-23
- 22 Whittle SB, Williamson KC, Russell HV. Incidence and risk factors of bacterial and fungal infection during induction chemotherapy for high-risk neuroblastoma. Pediatr Hematol Oncol 2017; 34 (05) 331-342
- 23 El-Mahallawy HA, Hassan SS, El-Wakil M, Moneer MM, Shalaby L. Increasing antimicrobial resistance monitored in surveillance analysis of blood stream infections in febrile neutropenic pediatric oncology patients. Asian Pac J Cancer Prev 2015; 16 (14) 5691-5695
- 24 El-Mahallawy HA, El-Wakil M, Moneer MM, Shalaby L. Antibiotic resistance is associated with longer bacteremic episodes and worse outcome in febrile neutropenic children with cancer. Pediatr Blood Cancer 2011; 57 (02) 283-288
- 25 Esbenshade AJ, Pentima MC, Zhao Z. et al. Development and validation of a prediction model for diagnosing blood stream infections in febrile, non-neutropenic children with cancer. Pediatr Blood Cancer 2015; 62 (02) 262-268
- 26 Horasan ES, Ersoz G, Tombak A, Tiftik N, Kaya A. Bloodstream infections and mortality-related factors in febrile neutropenic cancer patients. Med Sci Monit 2011; 17 (05) CR304-CR309
- 27 Lubwama M, Phipps W, Najjuka CF. et al. Bacteremia in febrile cancer patients in Uganda. BMC Res Notes 2019; 12 (01) 464
- 28 Kamonrattana R, Sathitsamitphong L, Choeyprasert W, Charoenkwan P, Natesirinilkul R, Fanhchaksai K. A randomized, open-labeled, prospective controlled study to assess the efficacy of frontline empirical intravenous piperacillin/tazobactam monotherapy in comparison with ceftazidime plus amikacin for febrile neutropenia in pediatric oncology patients. APOCP 2019; 20: 2733-2737
- 29 Noronha V, Joshi A, Patil VM. et al. Pattern of infection, therapy, outcome and risk stratification of patients with febrile neutropenia in a tertiary care oncology hospital in India. Indian J Cancer 2014; 51 (04) 470-474
- 30 Mandal PK, Maji SK, Dolai TK. et al. Micro-organisms associated with febrile neutropenia in patients with haematological malignancies in a tertiary care hospital in Eastern India. Indian J Hematol Blood Transfus 2015; 31 (01) 46-50
- 31 Kokkayil P, Agarwal R, Mohapatra S. et al. Bacterial profile and antibiogram of blood stream infections in febrile neutropenic patients with haematological malignancies. J Infect Dev Ctries 2018; 12 (06) 442-447
- 32 Rose W, Veeraraghavan B, George B. Bloodstream infections in children with febrile neutropenia: Isolates and their antimicrobial susceptibility profile. Indian J Cancer 2015; 52 (04) 495-496
- 33 Singhal T, Shah S, Naik R. The microbial etiology and antimicrobial susceptibility of bloodstream infections in patients with cancer at a private tertiary care hospital in Mumbai, India. Indian J Cancer 2016; 53 (03) 452-453
- 34 Karanwal AB, Parikh BJ, Goswami P, Panchal HP, Parekh BB, Patel KB. Review of clinical profile and bacterial spectrum and sensitivity patterns of pathogens in febrile neutropenic patients in hematological malignancies: a retrospective analysis from a single center. Indian J Med Paediatr Oncol 2013; 34 (02) 85-88
- 35 Daef EA, Elsherbiny NM, Agban MN, Riad KF, Mohammed LF. bloodstream infections in febrile neutropenic pediatric cancer patients: microbiological and sepsis biomarkers insight. Egypt J Immunol 2018; 25 (02) 21-34
- 36 Nouér SA, Nucci M, Anaissie E. Tackling antibiotic resistance in febrile neutropenia: current challenges with and recommendations for managing infections with resistant gram-negative organisms. Expert Rev Hematol 2015; 8 (05) 647-658